EQRx Inc is a biotechnology company that develops and commercializes innovative medicines for the treatment of cancer and other diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
EQRx's mission is to develop high-quality, cost-effective medicines for patients with cancer and other serious diseases. The company's approach to drug development focuses on maximizing the efficiency of the drug development process, from research to clinical trials to commercialization. EQRx is dedicated to creating an innovative, sustainable model for drug development that can help to lower the cost of healthcare for patients and the healthcare system as a whole.
EQRx has a number of drugs in its pipeline, including EQ001, a monoclonal antibody that targets certain immune cells and has the potential to treat a range of autoimmune and inflammatory diseases. The company is also developing EQ004, a monoclonal antibody that targets CD6, a protein that plays a key role in immune system function and has the potential to treat a range of autoimmune and inflammatory diseases.
The company's investors include GV, ARCH Venture Partners, Nextech Invest, and Casdin Capital, among others.
|
